Serial analysis of biomarkers of acute pancreas allograft rejection

A. K. Cashion, O. Sabek, C. Driscoll, L. Gaber, Elizabeth Tolley, A. O. Gaber

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pancreas transplant recipients experience graft loss in spite of improvements in immunosuppressant therapies and diagnostic technologies. Therefore, a method to improve detection and management of acute rejection is needed. This longitudinal study investigated the usefulness of three biomarkers, granzyme B, perforin, and human leukocyte antigen-DR alpha (HLA-DR) measured by real-time PCR on peripheral blood mononuclear cells, for their ability to detect acute rejection and its resolution in 13 recipients of pancreas allograft. Data demonstrated that pre-transplant baseline expression of biomarkers decreased following the initiation of immunosuppression. Throughout follow-up (range 3-27 months), individuals without acute rejection episodes had little variation in their biomarker levels. Recipients with biopsy-proven rejection had a significant increase in the levels of biomarkers as early as five wk before clinical rejection diagnosis. Furthermore, all seven patients with biopsy-proven rejection demonstrated a decrease in the levels of granzyme B and perforin following the increased immunosuppression for the treatment of rejection. This is the first clinical serial measurement of biomarkers in recipients of pancreas transplants. The data demonstrate that upregulation of granzyme B, perforin, and HLA-DR in peripheral blood mononuclear cells are sensitive to changes in the immune environment and could possibly be used to identify those patients at higher risk of rejection.

Original languageEnglish (US)
JournalClinical Transplantation
Volume24
Issue number6
DOIs
StatePublished - Nov 1 2010

Fingerprint

Allografts
Pancreas
Biomarkers
HLA Antigens
Immunosuppression
Blood Cells
Transplants
Biopsy
Immunosuppressive Agents
Longitudinal Studies
Real-Time Polymerase Chain Reaction
Up-Regulation
Technology
Therapeutics
perforin-granzyme B
Transplant Recipients

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Serial analysis of biomarkers of acute pancreas allograft rejection. / Cashion, A. K.; Sabek, O.; Driscoll, C.; Gaber, L.; Tolley, Elizabeth; Gaber, A. O.

In: Clinical Transplantation, Vol. 24, No. 6, 01.11.2010.

Research output: Contribution to journalArticle

Cashion, A. K. ; Sabek, O. ; Driscoll, C. ; Gaber, L. ; Tolley, Elizabeth ; Gaber, A. O. / Serial analysis of biomarkers of acute pancreas allograft rejection. In: Clinical Transplantation. 2010 ; Vol. 24, No. 6.
@article{79bcf1c7d75f41ffb2223bae9ac34a2b,
title = "Serial analysis of biomarkers of acute pancreas allograft rejection",
abstract = "Pancreas transplant recipients experience graft loss in spite of improvements in immunosuppressant therapies and diagnostic technologies. Therefore, a method to improve detection and management of acute rejection is needed. This longitudinal study investigated the usefulness of three biomarkers, granzyme B, perforin, and human leukocyte antigen-DR alpha (HLA-DR) measured by real-time PCR on peripheral blood mononuclear cells, for their ability to detect acute rejection and its resolution in 13 recipients of pancreas allograft. Data demonstrated that pre-transplant baseline expression of biomarkers decreased following the initiation of immunosuppression. Throughout follow-up (range 3-27 months), individuals without acute rejection episodes had little variation in their biomarker levels. Recipients with biopsy-proven rejection had a significant increase in the levels of biomarkers as early as five wk before clinical rejection diagnosis. Furthermore, all seven patients with biopsy-proven rejection demonstrated a decrease in the levels of granzyme B and perforin following the increased immunosuppression for the treatment of rejection. This is the first clinical serial measurement of biomarkers in recipients of pancreas transplants. The data demonstrate that upregulation of granzyme B, perforin, and HLA-DR in peripheral blood mononuclear cells are sensitive to changes in the immune environment and could possibly be used to identify those patients at higher risk of rejection.",
author = "Cashion, {A. K.} and O. Sabek and C. Driscoll and L. Gaber and Elizabeth Tolley and Gaber, {A. O.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1399-0012.2010.01285.x",
language = "English (US)",
volume = "24",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Serial analysis of biomarkers of acute pancreas allograft rejection

AU - Cashion, A. K.

AU - Sabek, O.

AU - Driscoll, C.

AU - Gaber, L.

AU - Tolley, Elizabeth

AU - Gaber, A. O.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Pancreas transplant recipients experience graft loss in spite of improvements in immunosuppressant therapies and diagnostic technologies. Therefore, a method to improve detection and management of acute rejection is needed. This longitudinal study investigated the usefulness of three biomarkers, granzyme B, perforin, and human leukocyte antigen-DR alpha (HLA-DR) measured by real-time PCR on peripheral blood mononuclear cells, for their ability to detect acute rejection and its resolution in 13 recipients of pancreas allograft. Data demonstrated that pre-transplant baseline expression of biomarkers decreased following the initiation of immunosuppression. Throughout follow-up (range 3-27 months), individuals without acute rejection episodes had little variation in their biomarker levels. Recipients with biopsy-proven rejection had a significant increase in the levels of biomarkers as early as five wk before clinical rejection diagnosis. Furthermore, all seven patients with biopsy-proven rejection demonstrated a decrease in the levels of granzyme B and perforin following the increased immunosuppression for the treatment of rejection. This is the first clinical serial measurement of biomarkers in recipients of pancreas transplants. The data demonstrate that upregulation of granzyme B, perforin, and HLA-DR in peripheral blood mononuclear cells are sensitive to changes in the immune environment and could possibly be used to identify those patients at higher risk of rejection.

AB - Pancreas transplant recipients experience graft loss in spite of improvements in immunosuppressant therapies and diagnostic technologies. Therefore, a method to improve detection and management of acute rejection is needed. This longitudinal study investigated the usefulness of three biomarkers, granzyme B, perforin, and human leukocyte antigen-DR alpha (HLA-DR) measured by real-time PCR on peripheral blood mononuclear cells, for their ability to detect acute rejection and its resolution in 13 recipients of pancreas allograft. Data demonstrated that pre-transplant baseline expression of biomarkers decreased following the initiation of immunosuppression. Throughout follow-up (range 3-27 months), individuals without acute rejection episodes had little variation in their biomarker levels. Recipients with biopsy-proven rejection had a significant increase in the levels of biomarkers as early as five wk before clinical rejection diagnosis. Furthermore, all seven patients with biopsy-proven rejection demonstrated a decrease in the levels of granzyme B and perforin following the increased immunosuppression for the treatment of rejection. This is the first clinical serial measurement of biomarkers in recipients of pancreas transplants. The data demonstrate that upregulation of granzyme B, perforin, and HLA-DR in peripheral blood mononuclear cells are sensitive to changes in the immune environment and could possibly be used to identify those patients at higher risk of rejection.

UR - http://www.scopus.com/inward/record.url?scp=78649893451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649893451&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2010.01285.x

DO - 10.1111/j.1399-0012.2010.01285.x

M3 - Article

VL - 24

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -